win 55,212-2

WIN 55,212-2 Mesylate ((R)-(+)-WIN 55212) is a potent aminoalkylindole cannabinoid (CB) receptor agonist with Kis of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively. Cannabinoid analogue WIN 55,212-2 Mesylate exhibited a novel anticancer effect against human tumors.

WRW4 TFA (878557-55-2 free base) is a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC50 of 0.23 μM. WRW4 TFA(878557-55-2 free base) specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide.

SARS-CoV-2-IN-55 (compound 65) is a SARS-CoV-2 inhibitor with low cytotoxicity, characterized by an IC50 of 0.3 μM, and acts through direct interaction with VSV-S pseudoparticles [1].

[Sar9,Met(O2)11]-Substance P TFA is a selective tachykinin NK1 receptor agonist.[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissi

Cannabipiperidiethanone, a synthetic cannabinoid structurally similar to JWH 250 and AM2233, has been detected in prohibited herbal blends in Japan. It exhibits affinity for CB1 and CB2 receptors with IC50 values of 591 nM and 968 nM, respectively. Compared to JWH 250, its affinities for CB1 and CB2 receptors are 2.3- and 9.4-fold lower, and 13- and 70-fold lower than (R)-(+)-WIN 55,212-2, respectively. Cannabipiperidiethanone is designated for forensic and research purposes only.

JWH 020, a cannabimimetic indole derivative of WIN 55,212-1, exhibits notably weaker affinities for the cannabinoid receptors CB1 and CB2 (128 and 205 nM, respectively) compared to WIN 55,212-2 (1.89 and 0.28 nM, respectively). The in vivo effects of JWH 020 have not been studied. This compound is designed for forensic and research purposes.